Burns J W & Co. Inc. NY Decreases Stock Holdings in Johnson & Johnson $JNJ

Key Points

• Burns J W & Co. Inc. NY decreased its stake in Johnson & Johnson by 2.8% in the second quarter, resulting in ownership of 53,901 shares valued at approximately $8.23 million.
• Insider trading was noted as EVP Jennifer L. Taubert sold 56,471 shares at an average price of $177.81, reducing her ownership by 24.08%.
• Johnson & Johnson announced a quarterly dividend of $1.30, translating to an annualized dividend of $5.20 and a yield of 3.0%.

Burns J W & Co. Inc. NY reduced its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 53,901 shares of the company's stock after selling 1,526 shares during the quarter. Johnson & Johnson makes up 1.0% of Burns J W & Co. Inc. NY's holdings, making the stock its 27th largest position. Burns J W & Co. Inc. NY's holdings in Johnson & Johnson were worth $8,233,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently made changes to their positions in the stock. ARS Wealth Advisors Group LLC lifted its stake in shares of Johnson & Johnson by 3.6% during the 2nd quarter. ARS Wealth Advisors Group LLC now owns 123,367 shares of the company's stock worth $18,844,000 after purchasing an additional 4,344 shares during the last quarter. Redhawk Wealth Advisors Inc. raised its stake in Johnson & Johnson by 4.6% in the second quarter. Redhawk Wealth Advisors Inc. now owns 3,009 shares of the company's stock valued at $460,000 after buying an additional 132 shares during the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of Johnson & Johnson by 104.2% in the second quarter. Exchange Traded Concepts LLC now owns 173,966 shares of the company's stock valued at $26,573,000 after purchasing an additional 88,777 shares during the period. Family Legacy Financial Solutions LLC acquired a new position in shares of Johnson & Johnson in the second quarter valued at about $423,000. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in shares of Johnson & Johnson by 1.5% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 1,724,086 shares of the company's stock valued at $268,975,000 after purchasing an additional 25,255 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.16% of the company's stock.

Johnson & Johnson Trading Up 1.0%

JNJ opened at $175.97 on Friday. The business has a fifty day moving average price of $172.80 and a 200 day moving average price of $161.69. The stock has a market capitalization of $423.80 billion, a price-to-earnings ratio of 18.82, a PEG ratio of 2.22 and a beta of 0.40. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $181.16. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business's quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's payout ratio is presently 55.61%.

Analysts Set New Price Targets

Several research firms recently commented on JNJ. Royal Bank Of Canada raised their target price on Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. JPMorgan Chase & Co. raised their target price on Johnson & Johnson from $185.00 to $200.00 and gave the company a "neutral" rating in a research report on Tuesday. Citigroup lifted their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a research report on Thursday, August 21st. Bank of America lifted their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Thursday, July 17th. Finally, Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $177.87.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.